Patients in the device group demonstrated lower rates of both cardiovascular mortality ( @ events per @ patient-years for the device group -LSB- @/@ patients , @ % -RSB- vs @ events per @ patient-years with warfarin -LSB- @/@ patients , @ % -RSB- ; hazard ratio -LSB- HR -RSB- , @ ; @ % CI , @-@ @ ; P = @ ) and all-cause mortality ( @ events per @ patient-years for the device group -LSB- @/@ patients , @ % -RSB- vs @ events per @ patient-years with warfarin -LSB- @/@ patients , @ % -RSB- ; HR , @ ; @ % CI , @-@ @ ; P = @ ) .